- TheStreet.com•5 hours ago
Merck (MRK) stock is slipping this morning as the company expects to post fiscal 2016 second quarter results before tomorrow's market open.
- Market Realist•6 hours ago
Remicade is marketed by Merck in Europe, Russia, and Turkey. Remicade's revenue is expected to decline by over 27% to $330 million in 2Q16, as compared to $455 million in 2Q15.
Merck & Co. Inc.NYSE
After hours: 58.40-0.03 (-0.05%) as of 4:38 PM EDT
|Bid||58.39 x 9300|
|Ask||58.40 x 1800|
|52wk Range||45.69 - 60.07|
|Day's Range||58.11 - 58.59|
|Avg Vol (3m)||8,835,825|
As of 4:00 PM EDT. Market closed.